CULLINAN THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
CULLINAN THERAPEUTICS, INC. (CGEM) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $3.34 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-03-10
- CULLINAN THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2025 was $3.34M, a 9.68% decline from fiscal 2024.
- CULLINAN THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2024 was $3.70M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2025-12-31 | $3.34M 10-K · filed 2026-03-10 |
| 2024-12-31 | $3.70M 10-K · filed 2026-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |